HOME >> MEDICINE >> NEWS
Study tests oral insulin to prevent type 1 diabetes

autoantibodies to glutamate decarboxylase (GAD), IA-2, and to insulin itself indicate a greater risk for developing type 1 diabetes. For a person with high-risk genes and all three antibodies, the risk of developing diabetes in the next 5 years is greater than 50 percent.

First- and second-degree relatives of people with type 1 diabetes who may be at risk are being screened through TrialNets natural history study, which is examining the immune and metabolic events that precede diabetes symptoms. Screening involves a simple blood test for the autoantibodies that signify diabetes risk. Individuals enrolled in the natural history study are closely monitored for diabetes development and may be eligible to participate in the oral insulin trial or future studies that try to arrest the autoimmune process.

Studies for the Newly Diagnosed

TrialNet studies are also aimed at safely preserving insulin production in people recently diagnosed with type 1 diabetes. In the few months after diagnosis, most patients still have a supply of functioning beta cells that, with the help of insulin injections, contribute to good control of blood glucose. If beta cells can be protected, more patients would be able to tightly control their blood glucose, which prevents or delays damage to the eyes, nerves, kidneys, heart, and blood vessels.

One TrialNet study seeks to turn off the immune attack on beta cells with Rituximab, a monoclonal antibody that binds to and temporarily destroys a specific class of immune cells. The Rituximab trial is recruiting patients with type 1 diabetes diagnosed within the previous 3 months. Rituximab is approved by the Food and Drug Administration (FDA) to treat specific forms of lymphoma and moderate to severe rheumatoid arthritis. It is not approved for the prevention of type 1 diabetes.

Also under way is a study testing whether mycophenolate mofetil (MMF) or MMF plus daclizumab (DZB), drugs appro
'"/>

Contact: Joan Chamberlain
niddkmedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
31-Jan-2007


Page: 1 2 3

Related medicine news :

1. Study, meta-analysis examine factors associated with death from heatstroke
2. Study says COPD testing is not measuring up
3. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
4. Study reveals gaps in vaccine financing for underinsured children
5. Study suggests nonpharmaceutical interventions may be helpful in severe influenza outbreaks
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
8. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
9. Study outlines how stroke, head injury can increase risk of Alzheimers disease
10. Study identifies new regulator of fat metabolism
11. Study shows Diachrome improves blood sugar control in people with type 2 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study tests oral insulin prevent type diabetes

(Date:4/1/2015)... (PRWEB) April 01, 2015 Pricing Healthcare ... last several months, bring coverage to a third of all ... states of Massachusetts, Kansas, and Iowa, and the first dedicated eye ... center in Dallas, TX was also added. , In addition, the ... to and general interest in the platform continue to grow across ...
(Date:4/1/2015)... With so much wet weather over the past ... their time indoors. When all this time is spent inside, ... latest article from Clean Crawls offers excellent advice to ... , One of the ways to improve the air ... The article states that, “Toluene, Xylene, and Benzene are all ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 "Giving credit ... to form. Its rewards are inestimable." - Loretta Young ... individuals in the water resources profession. The Call ... Please consider nominating yourself, a colleague, or organization for ... 2015. Learn more about the AWRA Awards and view ...
(Date:4/1/2015)... Decora Preset 30 Minute Countdown Timer, a ... Hardware City.’ The product helps in automatically switching off any ... the related electronic device is automatically turned off after the ... said, “We are glad that this amazing product is now ... Timer Switch in just a few clicks. The product has ...
(Date:4/1/2015)... TCS Healthcare Technologies (TCS), a leading provider ... and population health arenas, is pleased to announce a ... is fully integrated with the ACUITY platform. , The ... ET, will be led by Jeff Frater, RN, BSN, ... the feature-rich portal as well as the importance of ...
Breaking Medicine News(10 mins):Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 2Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 3Health News:3 Simple Ways to Improve Home Air Quality Listed by Clean Crawls in Latest Article 2Health News:Nominations Sought for National Water Resources Awards and Student Scholarships 2Health News:Nominations Sought for National Water Resources Awards and Student Scholarships 3Health News:Leviton Decora Preset 30 Minute Countdown Timer Available On TheHardwareCity.com 2Health News:TCS Healthcare Technologies Releases Acuity Connect 2Health News:TCS Healthcare Technologies Releases Acuity Connect 3
(Date:4/1/2015)... 1, 2015  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development and commercialization of a once-daily, ... and cholesterol gallstones, today announced that it has ... of Clinical Operations. Mr. Tonelli brings ... development and regulatory affairs.  From 2005 to 2014, ...
(Date:4/1/2015)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... office-based dental, animal health and medical practitioners, announced today ... company GmbH.  scil animal care is a highly specialized ... and services to veterinarians primarily in North ... on January 19, 2015. scil animal care ...
(Date:3/31/2015)... , March 31, 2015 Neurocrine Biosciences, Inc. ... entered into an exclusive collaboration and licensing agreement for ... in Japan and other select ... Mitsubishi Tanabe intends to initially develop NBI-98854 in ... Huntington,s disease and tardive dyskinesia. Neurocrine retains full commercial ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 2Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 3Henry Schein Completes Acquisition of scil animal care 2Henry Schein Completes Acquisition of scil animal care 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4
Cached News: